Drug profile · INN
rescinnamine
CINNASIL
rescinnamine (CINNASIL) is a synaptic vesicular amine transporter inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — rescinnamine
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
rescinnamine (CINNASIL) is a synaptic vesicular amine transporter inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Synaptic vesicular amine transporter inhibitor
Primary target: Synaptic vesicular amine transporter
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is rescinnamine?
rescinnamine (CINNASIL) is a synaptic vesicular amine transporter inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for rescinnamine?
CINNASIL is a marketed brand name for rescinnamine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of rescinnamine?
rescinnamine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.